Crystal Structure Analysis Supports Bimekizumab’s IL-17 Dual InhibitionÂ
In a recent study published in the Journal of Investigative Dermatology, researchers employed X-ray crystallography to gain insights into how bimekizumab (Bimzelx; UCB) binds to interleukin (IL)-17F. Adams et al






